125 related articles for article (PubMed ID: 21842128)
1. The role of serum response factor in hepatocellular carcinoma: an association with matrix metalloproteinase.
Kim KR; Bae JS; Choi HN; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2011 Dec; 26(6):1567-72. PubMed ID: 21842128
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma.
Zhao WB; Li Y; Liu X; Zhang LY; Wang X
Int J Mol Med; 2008 Aug; 22(2):187-92. PubMed ID: 18636172
[TBL] [Abstract][Full Text] [Related]
3. Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition.
Park MY; Kim KR; Park HS; Park BH; Choi HN; Jang KY; Chung MJ; Kang MJ; Lee DG; Moon WS
Int J Oncol; 2007 Dec; 31(6):1309-15. PubMed ID: 17982656
[TBL] [Abstract][Full Text] [Related]
4. Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway.
Yue P; Gao ZH; Xue X; Cui SX; Zhao CR; Yuan Y; Yin Z; Inagaki Y; Kokudo N; Tang W; Qu XJ
Eur J Cancer; 2011 May; 47(7):1115-24. PubMed ID: 21349701
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
Matsunaga Y; Koda M; Murawaki Y
Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
[TBL] [Abstract][Full Text] [Related]
6. The role of serum response factor in hepatocellular carcinoma: implications for disease progression.
Kwon CY; Kim KR; Choi HN; Chung MJ; Noh SJ; Kim DG; Kang MJ; Lee DG; Moon WS
Int J Oncol; 2010 Oct; 37(4):837-44. PubMed ID: 20811705
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of decreased nidogen-2 expression in the tumor tissue and serum of patients with hepatocellular carcinoma.
Cheng ZX; Huang XH; Wang Q; Chen JS; Zhang LJ; Chen XL
J Surg Oncol; 2012 Jan; 105(1):71-80. PubMed ID: 21815147
[TBL] [Abstract][Full Text] [Related]
8. Fascin-1 expression correlates with repression of E-cadherin expression in hepatocellular carcinoma cells and augments their invasiveness in combination with matrix metalloproteinases.
Hayashi Y; Osanai M; Lee GH
Cancer Sci; 2011 Jun; 102(6):1228-35. PubMed ID: 21323792
[TBL] [Abstract][Full Text] [Related]
9. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells.
Kim JR; Kim CH
Int J Biochem Cell Biol; 2004 Nov; 36(11):2293-306. PubMed ID: 15313474
[TBL] [Abstract][Full Text] [Related]
10. Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6.
Farra R; Dapas B; Pozzato G; Giansante C; Heidenreich O; Uxa L; Zennaro C; Guarnieri G; Grassi G
Biochimie; 2010 May; 92(5):455-63. PubMed ID: 20144681
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation.
Nart D; Yaman B; Yilmaz F; Zeytunlu M; Karasu Z; Kiliç M
Liver Transpl; 2010 May; 16(5):621-30. PubMed ID: 20440771
[TBL] [Abstract][Full Text] [Related]
12. Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Bae JS; Noh SJ; Kim KM; Jang KY; Chung MJ; Kim DG; Moon WS
Int J Oncol; 2014 Jan; 44(1):129-36. PubMed ID: 24173109
[TBL] [Abstract][Full Text] [Related]
13. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential.
Arii S; Mise M; Harada T; Furutani M; Ishigami S; Niwano M; Mizumoto M; Fukumoto M; Imamura M
Hepatology; 1996 Aug; 24(2):316-22. PubMed ID: 8690399
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism of enhanced invasiveness of human hepatocellular carcinoma by integrin alpha 6 beta 1].
Lu Y; Zhou R
Zhonghua Zhong Liu Za Zhi; 2000 Jul; 22(4):287-9. PubMed ID: 11778551
[TBL] [Abstract][Full Text] [Related]
16. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of certain apoptosis and angiogenesis factors in hepatocellular carcinoma].
Guo RP; Zhong C; Shi M; Zhang CQ; Wei W; Zhang YQ; Li JQ
Zhonghua Wai Ke Za Zhi; 2006 Dec; 44(23):1626-30. PubMed ID: 17359695
[TBL] [Abstract][Full Text] [Related]
18. Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex.
Choi HN; Kim KR; Lee JH; Park HS; Jang KY; Chung MJ; Hwang SE; Yu HC; Moon WS
Oncol Rep; 2009 Jan; 21(1):57-63. PubMed ID: 19082443
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression.
Chen RX; Xia YH; Xue TC; Ye SL
Mol Biol Rep; 2011 Aug; 38(6):3671-7. PubMed ID: 21104439
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of extracellular matrix in the liver induces high metastatic potential of hepatocellular carcinoma to the lung.
Sawada S; Murakami K; Murata J; Tsukada K; Saiki I
Int J Oncol; 2001 Jul; 19(1):65-70. PubMed ID: 11408924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
